Literature DB >> 28083765

An introduction to CKD-MBD research: restart for the future.

Masafumi Fukagawa1, Masaaki Inaba2, Keitaro Yokoyama3, Takashi Shigematsu4, Ryoichi Ando5, Ken-Ichi Miyamoto6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28083765     DOI： 10.1007/s10157-016-1372-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN： 1342-1751            Impact factor:   2.801


× No keyword cloud information.
  19 in total

1.  Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder.

Authors:  Masafumi Fukagawa; Keitaro Yokoyama; Fumihiko Koiwa; Masatomo Taniguchi; Tetsuo Shoji; Junichiro James Kazama; Hirotaka Komaba; Ryoichi Ando; Takatoshi Kakuta; Hideki Fujii; Msasaaki Nakayama; Yugo Shibagaki; Seiji Fukumoto; Naohiko Fujii; Motoshi Hattori; Akira Ashida; Kunitoshi Iseki; Takashi Shigematsu; Yusuke Tsukamoto; Yoshiharu Tsubakihara; Tadashi Tomo; Hideki Hirakata; Tadao Akizawa
Journal:  Ther Apher Dial       Date:  2013-06       Impact factor: 1.762

Review 2.  Mineral and bone disorders in kidney transplant recipients: reversible, irreversible, and de novo abnormalities.

Authors:  Takashi Hirukawa; Takatoshi Kakuta; Michio Nakamura; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2015-05-02       Impact factor: 2.801

Review 3.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

Review 4.  Management of phosphorus load in CKD patients.

Authors:  Yutaka Taketani; Fumihiko Koiwa; Keitaro Yokoyama
Journal:  Clin Exp Nephrol       Date:  2016-11-28       Impact factor: 2.801

Review 5.  Research on kidney and mineral metabolism in Japan: past, present, and future.

Authors:  Masahide Mizobuchi; Hiroaki Ogata; Fumihiko Koiwa; Eriko Kinugasa; Tadao Akizawa
Journal:  Clin Exp Nephrol       Date:  2016-12-22       Impact factor: 2.801

6.  Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.

Authors:  Francesca Tentori; Mia Wang; Brian A Bieber; Angelo Karaboyas; Yun Li; Stefan H Jacobson; Vittorio E Andreucci; Masafumi Fukagawa; Luc Frimat; David C Mendelssohn; Friedrich K Port; Ronald L Pisoni; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2014-12-16       Impact factor: 8.237

Review 7.  The kidney and bone metabolism: Nephrologists' point of view.

Authors:  Masafumi Fukagawa; Yasuhiro Hamada; Shohei Nakanishi; Motoko Tanaka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

8.  Association of comorbid conditions and mortality in hemodialysis patients in Europe, Japan, and the United States: the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  David A Goodkin; Jennifer L Bragg-Gresham; Karl G Koenig; Robert A Wolfe; Takashi Akiba; Vittorio E Andreucci; Akira Saito; Hugh C Rayner; Kiyoshi Kurokawa; Friedrich K Port; Philip J Held; Eric W Young
Journal:  J Am Soc Nephrol       Date:  2003-12       Impact factor: 10.121

9.  Serum phosphate and calcium should be primarily and consistently controlled in prevalent hemodialysis patients.

Authors:  Masatomo Taniguchi; Masafumi Fukagawa; Naohiko Fujii; Takayuki Hamano; Tetsuo Shoji; Keitaro Yokoyama; Shigeru Nakai; Takashi Shigematsu; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Ther Apher Dial       Date:  2013-04       Impact factor: 1.762

Review 10.  Phosphate-a poison for humans?

Authors:  Hirotaka Komaba; Masafumi Fukagawa
Journal:  Kidney Int       Date:  2016-06-07       Impact factor: 10.612
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.